Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | CD74 | P04233 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19133994 | 0.85 | CDC7 (0.70) | KMOCDC7DHODHTSHREGFR | |
| SCHEMBL4181380 | 0.83 | CDC7 (0.73) | KMOCDC7NOTUMCD74MIF | |
| SCHEMBL8963513 | 0.80 | TSHR (0.53) | CDC7CASP3SENP8SENP7SENP6 | |
| SCHEMBL10939203 | 0.80 | KDM4E (0.42) | KMOCDC7CASP3SENP8SENP7 | |
| SCHEMBL27723391 | 0.77 | KDM5A (0.46) | NOTUMDAOTSHRNAPRTRAB9A | |
| SCHEMBL3639904 | 0.76 | PARP1 (0.50) | KMONOTUMDHODHKDM4E | |
| SCHEMBL11551276 | 0.76 | KDM4E (0.50) | DHODHKDM4EGAA | |
| SCHEMBL10937768 | 0.76 | CDC7 (0.39) | KMOCDC7CASP3SENP8SENP7 | |
| SCHEMBL1516884 | 0.75 | KMO (0.74) | KMODHODHDAOTSHRNAPRT | |
| SCHEMBL25352091 | 0.74 | LMNA (0.59) | TSHRKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850146-A | Synthetic cannabinoid hapten compound and preparation method and application thereof | 上海市禁毒委员会办公室 | 2023-03-28 | — | — | CN | claimed |
| CN-112823151-B | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024009283-A1 | AT2 ANTAGONISTS FOR NON-ADDICTIVE PAIN RELIEF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-115850146-A | Synthetic cannabinoid hapten compound and preparation method and application thereof | 上海市禁毒委员会办公室 | 2023-03-28 | — | — | CN | disclosed |
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
| CN-112823151-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-3818044-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-101300229-B | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL | 2011-10-05 | — | — | CN | disclosed |
| CN-101300229-A | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2008-11-05 | — | — | CN | disclosed |
| CN-1325385-A | Gastrin and cholecystokinin receptor ligands | BLACK JAMES FOUNDATION (GB) | 2001-12-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KMO 4124/4885CDC7 644/4885NOTUM 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.